Skip to main content
CRVO
NASDAQ Life Sciences

CEO John Alam Buys 100,000 CRVO Shares for $152,621 Near 52-Week Low

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.317
Mkt Cap
$20.121M
52W Low
$1.27
52W High
$10
52W Position info
3.7% above low
Off High info
87% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CRVO is trading near its 52-week low of $1.27 (3.7% above the low).

Summary

CervoMed CEO and President John J. Alam bought 100,000 shares in the open market on November 18 at $1.51-$1.53, spending $152,621 and lifting his direct holdings to 1,584,078 shares.


Key Events · Ownership and Investor Activity · CRVO

  • CEO Open-Market Purchase

    John J. Alam, CEO, President and 10% owner, bought 100,000 shares on 2026-11-18 in two trades at $1.514 and $1.53, totaling $152,621.10.

  • Holdings Rise to 1.58M Shares

    Direct ownership after the purchase is 1,584,078 shares, plus 12,500 shares held in his spouse's IRA.

  • Buying at 52-Week Low

    The purchase prices of $1.51-$1.53 sit just above the 52-week low of $1.27, with the stock at $1.32 today.

  • Going-Concern Backdrop

    The Q3 2026 10-Q reported a $5.9 million net loss and $19.6 million of cash and securities with substantial doubt about continuing as a going concern.


Analysis · CRVO · Life Sciences

Why it matters: the CEO and President put $152,621 of his own money into open-market purchases at $1.51-$1.53, right at the stock's 52-week low of $1.27 and while the company carries a going-concern warning. This is real cash, not an option exercise or grant, and it is a meaningful stake increase for a nano-cap. It does not fix the balance sheet — CervoMed had $19.6 million of cash and securities at Q3 with substantial doubt about continuing as a going concern — but it shows the top executive buying into his own story after the Phase 2b DLB miss and the nfvPPA biomarker data.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRVO was trading at $1.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.1M. The 52-week trading range was $1.27 to $10.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRVO - Latest Insights

CRVO
Nov 16, 2026, 4:02 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.32 info
Change: -$0.3327 (-20%) info
Market Cap: $20.121M info
CRVO
Nov 06, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $1.32 info
Change: -$0.1027 (-7%) info
Market Cap: $20.121M info
CRVO
Oct 29, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.32 info
Change: -$0.4327 (-25%) info
Market Cap: $20.121M info
CRVO
Oct 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $1.32 info
Change: -$1.70 (-56%) info
Market Cap: $20.121M info
CRVO
Sep 28, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.32 info
Change: -$1.31 (-50%) info
Market Cap: $20.121M info